FOLD Stock Recent News
FOLD LATEST HEADLINES
FOLD reports preliminary fourth-quarter and full-year 2024 total revenues. The company also outlines key strategic goals for 2025.
2024 Total Revenue of $528M, Representing Significant Growth of 32% Year-Over-Year 1
PRINCETON, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 13, 2025, at 3:00 p.m. PT.
Amicus Therapeutics (FOLD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
On Thursday, Amicus Therapeutics FOLD announced that it has entered into a License Agreement with Teva Pharmaceuticals Inc. TEVA.
PRINCETON, N.J., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that three posters highlighting its development program for Pompe disease will be included at the 29th Annual Congress of the World Muscle Society being held October 8-12, 2024 in Prague, Czechia.
Amicus Therapeutics is making steady progress towards promised profitability, driven by the continued growth of Galafold and the launch of Pombiliti+Opfolda. The "beat-and-raise" guidance profile is missing this year and could partially explain the lack of the year-to-date share price momentum. Pombiliti+Opfolda's launch is progressing well, with patients switching from both Nexviazyme and Lumizyme.
PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in September.
Amicus' (FOLD) lead drug, Galafold, is witnessing solid sales uptake so far. The approval for Pombiliti + Opfolda also aids sales.
Amicus Therapeutics focuses on rare diseases like Fabry and Pompe, with Galafold and Pombiliti as main value drivers. Galafold is the only oral treatment for Fabry disease, stabilizing the alpha-Gal A enzyme and capturing significant market share. Pombiliti, combined with Opfolda, treats late-onset Pompe disease, showing strong adoption and receiving multiple awards for its efficacy.